Pfizer vs Moderna
Major global pharmaceutical company developing vaccines and medicines vs Healthcare sector company. Which is the better buy for your portfolio in October 2026? Plain-English answer below.
Pfizer parlayed its pandemic windfall into a massive acquisition spree, while Moderna is still running hard to diversify beyond its mRNA COVID franchise before the revenue cliff steepens. Both companies stake their futures on pipeline execution in a business where clinical failure can erase billions of market cap overnight. Pfizer vs Moderna forces you to weigh an established diversified pharma engine against a pure-play mRNA bet.
Pfizer parlayed its pandemic windfall into a massive acquisition spree, while Moderna is still running hard to diversify beyond its mRNA COVID franchise before the revenue cliff steepens. Both compani...
Why It’s Moving
Pfizer Gains FDA Approval for Expanded Prostate Cancer Treatment and Reports Strong Vaccine Data
- The FDA expanded approval of TALZENNA (talazoparib) combined with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer carrying HRR gene mutations, including non-BRCA variants.
- Detailed results from a Phase 2 study showed Pfizer's investigational 25-valent pediatric pneumococcal conjugate vaccine elicited robust immune responses against all 25 serotypes with safety comparable to PREVNAR 20.
- While the broader healthcare sector faced selling pressure due to disappointing distant spread data in Moderna's melanoma vaccine trial, Pfizer held steady and edged higher, benefiting from its specific positive clinical and regulatory updates.
Pfizer Gains FDA Approval for Expanded Prostate Cancer Treatment and Reports Strong Vaccine Data
- The FDA expanded approval of TALZENNA (talazoparib) combined with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer carrying HRR gene mutations, including non-BRCA variants.
- Detailed results from a Phase 2 study showed Pfizer's investigational 25-valent pediatric pneumococcal conjugate vaccine elicited robust immune responses against all 25 serotypes with safety comparable to PREVNAR 20.
- While the broader healthcare sector faced selling pressure due to disappointing distant spread data in Moderna's melanoma vaccine trial, Pfizer held steady and edged higher, benefiting from its specific positive clinical and regulatory updates.
Investment Analysis
Pfizer
PFE
Pros
- Pfizer maintains a wide economic moat from its established drug portfolio and brand strength.
- Pfizer offers a high dividend yield of around 6.74% to shareholders.
- Pfizer exhibits low stock volatility of approximately 5.6%, reducing price fluctuation risk.
Considerations
- Pfizer anticipates a 23% decline in its COVID-19 business, pressuring 2026 revenues.
- Pfizer faces a looming patent cliff on key best-selling drugs, risking revenue losses.
- Pfizer trimmed its FY2026 profit forecast to $2.80-$3 per share, below analyst estimates.
Moderna
MRNA
Pros
- Moderna projects 10% revenue growth for 2026, driven by pipeline advancements.
- Moderna holds a healthy current ratio of 3.93, ensuring strong liquidity coverage.
- Moderna anticipates key 2026 catalysts from its Phase III melanoma trial readout.
Considerations
- Moderna reports high stock volatility of nearly 20%, increasing investment risk.
- Moderna experienced a 56% revenue decline over the last twelve months with negative EBITDA.
- Moderna shows a negative gross profit margin of -107.62%, indicating ongoing unprofitability.
Pfizer (PFE) Next Earnings Date
Pfizer has a confirmed upcoming earnings report scheduled for November 3, 2026, at 10:00 AM ET before the market opens. This release will cover the company's financial performance for the third quarter of 2026. Investors should note that this date aligns with Pfizer's historical pattern of reporting approximately three months after its previous August announcement.
Pfizer (PFE) Next Earnings Date
Pfizer has a confirmed upcoming earnings report scheduled for November 3, 2026, at 10:00 AM ET before the market opens. This release will cover the company's financial performance for the third quarter of 2026. Investors should note that this date aligns with Pfizer's historical pattern of reporting approximately three months after its previous August announcement.
Buy PFE or MRNA in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
